Day: February 21, 2018

Novo Nordisk Launches Rebinyn in the United States for People with Hemophilia B

Note: The following is an excerpt from a press release from Novo Nordisk. Read the full press release here.  Novo Nordisk, a global healthcare company, today announced that Rebinyn, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the treatment of hemophilia B.Rebinyn is an extended half-life injectable medicine used to treat […]